If you’ve spent any time around wellness or healthy aging lately, you’ve probably heard at least one of the names.
BPC-157. GHK-Cu. TB-500. MOTS-C. Semax. Epitalon.
Maybe someone mentioned peptides for recovery. You heard about one for skin or collagen. Another supposedly has something to do with metabolism or energy. Then you started looking around and discovered there seems to be a peptide for just about everything.
At that point, I think most people have the same question: What exactly are these things, and why is everyone suddenly talking about them?
Let’s start there.
Peptides aren’t actually new, and they aren’t one treatment. Your body makes peptides naturally, and scientists have been studying and using peptide-based medicines for years. What’s new is how quickly a much broader group of peptides has moved into conversations about wellness, recovery and healthy aging.
And some of that science is genuinely interesting.
Your Body Is Already Using Peptides
Here’s the easiest way I know to think about them.
Peptides are small chains of amino acids, the same building blocks used to make proteins. Many peptides in the body act somewhat like messengers, helping cells and systems communicate about what needs to happen.
That can involve all sorts of functions, depending on the peptide.
This is part of what makes them so interesting to researchers. If scientists understand that a particular peptide or pathway is involved in something like appetite, hormone signaling, tissue response or metabolism, they can investigate whether that biology might be useful therapeutically.
We’ve already seen that happen.
Semaglutide and tirzepatide are familiar examples of medicines built around peptide biology. Other peptide or peptide-based drugs are used in established medical care as well.
So the idea that a peptide can have a meaningful effect in the human body isn’t speculative.
The question is which peptide, doing what?
That’s where the conversation gets more interesting.
Skin, Recovery, Metabolism, Brain Health—Why So Many Claims?
This is the part that can make the peptide world feel a little like alphabet soup.
GHK-Cu gets talked about around skin, collagen and tissue health. BPC-157 and TB-500 tend to show up in conversations about recovery and repair. MOTS-C has attracted attention around cellular energy and metabolism. Semax is discussed in connection with neurological and cognitive research. Epitalon has become part of some longevity conversations.
Those associations aren’t random. There are biological reasons researchers have become interested in these substances.
But—and this is the part I want you to understand without needing a research degree—they are not all at the same place scientifically.
Think about how we use the word vehicle. A bicycle, sedan and airplane are all vehicles, but knowing that doesn’t tell you much about what each one can do.
“Peptide” works a little like that.
Some peptide-based drugs have been studied extensively in people, gone through the FDA approval process and are prescribed for specific medical conditions. Others have early human research. Some of the peptides getting the most attention in wellness circles have much more laboratory and animal research than good human clinical evidence.
That doesn’t mean the early science isn’t worth watching.
It means we shouldn’t assume everything carrying the peptide label comes with the same amount of proof.
This Is Where the Internet Can Get Ahead of the Science
Let’s say researchers discover that a substance affects a process involved in tissue repair in an animal study.
That’s interesting.
Then somewhere along the way, “researchers observed an effect involving tissue repair” becomes “supports recovery.” A few more steps and somebody is telling you it will heal your shoulder.
Those aren’t the same statement.
This happens all the time with emerging health science, not only peptides. Early findings are exciting precisely because they give us something new to investigate. But there is usually more work between an interesting biological finding and knowing that a treatment reliably produces a meaningful result in people.
That’s why you’ll hear me use words such as promising, emerging and established differently in The Well House.
Promising isn’t a polite way of saying something doesn’t work. It means there’s enough there to be interested, while there are still questions to answer.
Then Someone Mentions a Compounded Peptide
This is where people understandably get confused.
You may encounter a peptide through a clinician or wellness practice and assume that because it can be prescribed, it must be an FDA-approved medication.
Those aren’t necessarily the same thing.
Compounding has a legitimate role in healthcare and can allow pharmacies to prepare medications for particular patient needs. But a compounded medication does not go through the same FDA premarket approval process as an FDA-approved drug. The FDA specifically states that it does not review compounded drugs for safety, effectiveness or quality before they are marketed (U.S. Food and Drug Administration [FDA], 2026a).
This distinction matters with peptides because some of the names you’re hearing about in wellness and longevity settings are being discussed or used as compounded products rather than FDA-approved treatments for those particular purposes.
The regulatory picture is also changing. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee considered BPC-157-related substances, TB-500-related substances, MOTS-C-related substances, Semax-related substances and Epitalon-related substances as the FDA evaluates substances nominated for inclusion on its 503A Bulks List. The committee was asked to consider specific nominated uses for each substance; this process should not be confused with FDA approval of those peptides as drugs for general wellness or longevity purposes (FDA, 2026b).
You don’t need to memorize any of that.
Just remember this: available, prescribed, compounded and FDA approved don’t all mean the same thing.
If you’re considering a peptide, it’s reasonable to ask which one you’re receiving, where it comes from and what its current status is.
So How Do You Know What’s Worth Exploring?
I wouldn’t start with, “Are peptides good or bad?”
That’s too broad to be useful.
I’d start with what you’re hoping to change.
Are you interested because recovery isn’t what it used to be? Are you thinking about skin? Body composition? Metabolic health? Energy? Cognition? Something else?
Then we can talk about the particular peptide being considered for that goal. What do we actually know about it? Has it been meaningfully studied in people? What results have researchers found? What don’t we know yet? How is it being given? What are the potential downsides? Does your health history change the conversation? Are there other options with stronger evidence for what you’re trying to accomplish?
Those questions don’t take the excitement out of peptides.
They make the conversation useful.
Because there is a very big difference between saying, “I heard peptides are great for aging,” and saying, “I’m interested in this particular peptide for this particular reason, and I understand where the evidence stands.”
That’s informed curiosity.
And There Is Plenty More to Talk About
Peptides are fascinating partly because the category is so broad. The peptide involved in a well-established prescription medication and the peptide being discussed in a longevity podcast may belong to the same molecular family while having completely different levels of clinical evidence behind them.
That’s why we’re going to take these one at a time.
We’ll look at the peptides you’re actually hearing about. What people hope they’ll do. What the science says so far. Where the evidence is stronger, where it’s still developing and what new research may change the conversation.
You don’t need to learn all of it today.
For now, I want you to leave with one thing: when someone says “peptides,” don’t stop there.
Ask which one.
Because that’s when the interesting conversation really begins.
References
U.S. Food and Drug Administration. (2026a). Understanding the risks of compounded drugs. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2026b). July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2026c). Certain bulk drug substances for use in compounding that may present significant safety risks. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (n.d.). Bulk drug substances used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. U.S. Department of Health and Human Services.
Sources checked: August 16, 2026.